NWBO News and Press, Northwest Biotherapeutics Inc. From 03/09/23

2023-03-09 06:49:58 ET Cancer-focused biotech Northwest Biotherapeutics ( OTCQB:NWBO ) has entered into a loan agreement worth more than $11.0M with Utah-based Streeterville Capital LLC. Per the terms, the deal has a maturity of 22 months, and debt repayments will begin from N...

Summary The company does not offer a specific BLA filing date. They filed a major lawsuit against big name market makers, alleging stock price manipulation. NWBO has no cash. I see I am the only one covering Northwest Biotherapeutics ( NWBO ) on Seeking Alpha these day...

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023 PR Newswire 78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md. , Jan. 6, 2023 /PRNewswire/ -...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Northwest Biotherapeutics (OTCMKTS: NWBO ) are in focus on Thursday. NWBO stock is up about 5% on the day and it’s got investors’ attention with a lawsuit against Citadel Securities, among other fi...

Trading data shows that seven preeminent market makers engaged in market manipulation via spoofing to drive down Northwest Biotherapeutics' stock prices as the company worked to raise funds to bring breakthrough cancer treatments to market NEW YORK, NY / ACCESSWIRE / December 1, 2022 / Today...

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma PR Newswire Both Median Survival and " Long Tail " of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results...

Summary Despite those excellent results, Northwest Biotherapeutics stock remains uninvestable. If the company behaved like a normal company, announced official data, published, filed for approval - sued its detractors -  that would not have been the case. As it is, though...

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA PR Newswire PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/...

As is its wont, Northwest Biotherapeutics "progresses" at a snail's pace. NWBO stock is stagnant after that brief spurt in May. Among other problems, they have a fundamental problem with their cash runway. One more quarter, one more coverage of Northwest Bio ( OTCQB:NW...

CytoDyn Inc (OTCMKTS: CYDY) shares gained more than 8% closing the day at $0.73. CYDY has a market cap of over 524.8M$. CYDY is a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications. The company had announced the appointment o...